



October 25, 2016

## Cumberland Pharmaceuticals To Announce Third Quarter 2016 Financial Results

NASHVILLE, Tenn., Oct. 25, 2016 /PRNewswire/ -- **Cumberland Pharmaceuticals Inc.** (NASDAQ: CPIX) announced today that it will release third quarter 2016 financial results after the market closes on Tuesday, November 1, 2016. A conference call and live Internet webcast will be held on Tuesday, November 1, 2016, at 4:30 p.m. Eastern Time to discuss the results.



To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 99386514. The live webcast and rebroadcast can be accessed via Cumberland's website at <http://investor.shareholder.com/cpix/events.cfm>.

**Cumberland Pharmaceuticals Inc.** is a specialty pharmaceutical company focused on acquisition, development, and commercialization of high-quality products that improve the quality of care for patients. The Company has a diverse product portfolio with a focus in the areas of hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote<sup>®</sup> (*acetylcysteine*) Injection for the treatment of acetaminophen poisoning, Caldolor<sup>®</sup> (*ibuprofen*) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose<sup>®</sup> (*lactulose*) for Oral Solution, a prescription laxative, Vaprisol<sup>®</sup> (*conivaptan*) Injection, for the treatment of hyponatremia, Omeclamox-Pak<sup>®</sup> for the treatment of *H. pylori* and duodenal ulcer disease, and Ethyol<sup>®</sup> (*amifostine*) for Injection, for the treatment of oncology patients. Cumberland is dedicated to also developing innovative products that address unmet medical needs. The Company's product candidates in clinical development include: Hepatoren<sup>®</sup> (*ifetroban*) Injection for the treatment of hepatorenal syndrome, Boxaban<sup>®</sup> (*ifetroban*) Oral Capsule for patients suffering from aspirin exacerbated respiratory disease, and Vascular<sup>™</sup> (*ifetroban*) Oral Capsule for the treatment of systemic sclerosis. For more information on Cumberland Pharmaceuticals Inc., please visit [www.cumberlandpharma.com](http://www.cumberlandpharma.com).

Logo - <http://photos.prnewswire.com/prnh/20140505/84325>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-third-quarter-2016-financial-results-300350503.html>

SOURCE Cumberland Pharmaceuticals Inc.

News Provided by Acquire Media